NCT05439148 - OPC-61815 in Healthy Chinese Male Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2022

Primary Completion Date

September 21, 2022

Study Completion Date

September 21, 2022

Conditions

Healthy Adult Male

Interventions

DRUG

OPC-61815 injection

Intravenous administration of OPC-61815 at 8 mg or 16 mg. 8mg group will be intravenously administered only on D1, once a day. 16mg group will be intravenously administered on D1，D3-D9, once a day.

Trial Locations (1)

Unknown

Clinical Pharmacology Research Center, Peking Union Medical College Hospital, Beijing